F-flotufolastat shows a 69% detection rate for recurrent prostate cancer in patients with PSA levels above 0.2 ng/mL post-prostatectomy. The agent demonstrates a 50% detection rate for PSAs below 0.2 ...

Talazoparib plus enzalutamide significantly improved overall survival in mCRPC patients, including those with HRR gene mutations. The treatment's safety profile aligns with known data for talazoparib ...

"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter. As with most cases, we need to start with a review of the ...

SBRT shows promise in achieving progression-free survival in metastatic RCC without systemic therapy, despite limited high-level data. The absence of phase 3 trials leaves a gap in comparing SBRT ...

SunRISe-4 targets MIBC patients ineligible for or refusing cisplatin-based chemotherapy, addressing an unmet medical need. The trial evaluates TAR-200 plus cetrelimab and cetrelimab monotherapy, ...

Aquablation with HYDROS is a transurethral water jet procedure for BPH, combining resective and non-resective therapy benefits. The HYDROS system uses AI-powered treatment planning and real-time ...

The study evaluates Focal One robotic HIFU for BPH, focusing on safety and efficacy in a phase 1/2 trial. Phase 1 determines optimal treatment parameters, while phase 2 expands enrollment to assess ...

Lu-rhPSMA-10.1 injection demonstrated favorable radiation dosimetry and high tumor absorption in mCRPC patients, supporting progression to phase 2 trials. Phase 2 will investigate higher radioactivity ...

The new Category I code will become effective on January 1, 2026.

Demogeot discusses his team's GETUG 14 findings regarding early administration of ADT plus high-dose radiotherapy for intermediate to high risk prostate cancer. Findings from GETUG 14 show short-term ...